Meritage Homes enters the week with a fresh downgrade landing on the same day short interest hits its highest level in over a month — a convergence that puts the homebuilder's near-term narrative squarely in focus.
The most newsworthy development is today's action from Truist Securities. Analyst Jonathan Bettenhausen cut his rating from Buy to Hold and trimmed his target from $80 to $72 — the second time Truist has lowered its target this year, after an earlier reduction from $90 in April. At $65.78, the stock trades well below the Truist target, but the direction of travel matters: this is a bellwether homebuilding coverage name moving to the sidelines just six weeks before the next earnings print on October 28. The broader analyst picture remains mixed — Goldman Sachs maintained its Buy in July with a $93 target and UBS nudged its Buy target slightly higher to $88 — but the weight of recent moves has been downward, with JPMorgan, BofA, and Evercore all cutting targets earlier in the year while sitting at Neutral or In-Line.
Short positioning has accelerated sharply and is now the clearest data-driven tension in the stock. Short interest climbed to 6.9% of the free float — up 10% on the week and 38% over the past month, driven by a burst of new positioning since early September. The ORTEX short score has jumped from 45.7 to 51.6 in just two weeks, crossing the neutral threshold for the first time in this cycle. Despite the build, the borrow market remains untroubled: availability runs at 861%, meaning there are roughly eight-and-a-half shares available for every one already borrowed. Cost to borrow is just 0.46%, easing slightly on the week. Shorts are adding conviction, but there is no squeeze mechanics building — this is a directional bet, not a forced positioning story. The availability figure has also tightened dramatically from above 2,900% earlier in September, which flags how quickly the lending pool is being drawn down even if absolute levels remain comfortable.
Options positioning reinforces the cautious mood. The put/call ratio runs at 1.97 — essentially flat with its 20-day average of 1.97, but the level itself is striking. It hit a 52-week high of 2.48 on September 3 and remains far above the 52-week low of 0.23, placing options traders in firmly defensive territory for this stock. The z-score is near zero, meaning this is the new normal for MTH options, not a fresh spike — sustained put-heavy positioning rather than an acute hedging rush.
The valuation backdrop gives context to the caution. MTH trades at 11.4x trailing earnings, down sharply over the past 30 days, and at just 0.80x book — well below one. EV/EBITDA is at 9.6x, moving modestly higher on the week. Factor scores reflect the bifurcation: the dividend score ranks in the 91st percentile, but EPS momentum over 30 and 90 days sits in the 33rd and 27th percentiles respectively, signalling that estimate revisions remain under pressure. The bear case centres on the 13% post-Q2 EPS cut, margin compression, and elevated rates grinding against affordability. Against peers this week, MTH rose 2.1% — outperforming GRBK (-4.5%), LGIH (-4.6%), and KBH (-1.4%), while roughly tracking DHI (+1.2%) and PHM (-0.5%).
The key variable heading into October 28 earnings is whether deliveries and gross margin hold closer to the bull or bear scenario — the Truist downgrade today sharpens that question considerably.
See the live data behind this article on ORTEX.
Open MTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
